Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic
processes, including immunomodulation and cell proliferation. Tumors create an adenosine …

The development of endocrine resistance is a common reason for the failure of endocrine
therapies in hormone receptor-positive breast cancer. This review provides an overview of …

Clinical trials in cancer are ideally built on a foundation of sound mechanistic rationale and
well-validated drug activity in relevant disease models. The screening of approved and …

Pharmacogenomics (PGx) is the hope for the full optimization of drug therapy while
minimizing the accompanying adverse drug events that cost billions of dollars annually …

Drug discovery requires high cost and is a time-consuming process, and the facilitation of
computer-based drug design methods is one of the most potential approaches to change …

CRISPR/Cas technology is a powerful technique for gene editing, with impressive accuracy
and efficiency. It has the potential to revolutionize the treatment of genetic diseases and …

Drug repurposing can accelerate the development of novel therapeutic strategies. Oral
squamous cell carcinoma (OSCC) is prevalent in Asians and is associated with poor …

Abnormalities of FGFR1 have been reported in multiple malignancies, suggesting FGFR1 as
a potential target for precision treatment, but drug resistance remains a formidable obstacle …

ATF4 drives the resistance of T-ALL against FGFR1 inhibitors through amino acid metabolic
reprogramming Page 1 Page 1/34 ATF4 drives the resistance of T-ALL against FGFR1 inhibitors …

El desarrollo de biomarcadores es un problema prioritario para un gran número de
disciplinas, particularmente para la Toxicología, cuya enseñanza teórico-práctica forma …